Back to top

Image: Bigstock

Can IDI (COGT) Run Higher on Strong Earnings Estimate Revisions?

Read MoreHide Full Article

IDI, Inc. (COGT - Free Report)   is an IT Services company  that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on COGT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that IDIcould be a solid choice for investors.

Current Quarter Estimates for COGT

In the past 30 days, one estimate has gone higher for IDI while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 17 cents a share 30 days ago, to a loss of 13 cents today, a move of 23.5%.

Current Year Estimates for COGT

Meanwhile, IDI’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 55 cents per share 30 days ago to a loss of 41 cents per share today, an increase of 69%.

IDI, Inc. Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 6.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

 Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

 Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Cogent Biosciences, Inc. (COGT) - free report >>

Published in